Particle therapy in Europe

Cai Grau, Marco Durante, Dietmar Georg, Johannes A Langendijk, Damien C Weber, Cai Grau, Marco Durante, Dietmar Georg, Johannes A Langendijk, Damien C Weber

Abstract

Particle therapy using protons or heavier ions is currently the most advanced form of radiotherapy and offers new opportunities for improving cancer care and research. Ions deposit the dose with a sharp maximum - the Bragg peak - and normal tissue receives a much lower dose than what is delivered by X-ray therapy. Particle therapy has also biological advantages due to the high linear energy transfer of the charged particles around the Bragg peak. The introduction of particle therapy has been slow in Europe, but within the last decade, more than 20 clinical facilities have opened and facilitated access to this frontline therapy. In this review article, the basic concepts of particle therapy are reviewed along with a presentation of the current clinical indications, the European clinical research, and the established networks.

Keywords: cancer; ion beam therapy; particle therapy; proton therapy; radiation; radiotherapy.

Conflict of interest statement

The authors declare no conflict of interest.

© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Figures

Fig. 1
Fig. 1
Physical and biological advantages of particle therapy (protons and carbon ions) as compared to megavoltage X‐rays (photons). The depth–dose curves of charged particles are defined by a plateau phase and the Bragg peak, situated in a specific depth depending on the energy of the beam.
Fig. 2
Fig. 2
Graph showing the number of clinical proton facilities in Europe 2009–2020. Source: www.ptcog.ch.
Fig. 3
Fig. 3
Comparison of treatment plans with X‐rays (left) and protons (right) for different tumor sites. Figure reproduced from Durante et al. (2019), reproduced with permission of Elsevier.

References

    1. Beck N, van Brakel TJ, Smit HJM, van Klaveren D, Wouters M and Schreurs WH (2019) Pneumonectomy for lung cancer treatment in the Netherlands: between‐hospital variation and outcomes. World J Surg 44, 285–294.
    1. Bolsi A, Peroni M, Amelio D, Dasu A, Stock M, Toma‐Dasu I, Nystrom PW and Hoffmann A (2018) Practice patterns of image guided particle therapy in Europe: a 2016 survey of the European Particle Therapy Network (EPTN). Radiother Oncol 128, 4–8.
    1. Christianen ME, van der Schaaf A, van der Laan HP, Verdonck‐de Leeuw IM, Doornaert P, Chouvalova O, Steenbakkers RJ, Leemans CR, Oosting SF, van der Laan BF et al (2016) Swallowing sparing intensity modulated radiotherapy (SW‐IMRT) in head and neck cancer: clinical validation according to the model‐based approach. Radiother Oncol 118, 298–303.
    1. Dosanjh M, Amaldi U, Mayer R, Poetter R and Network E (2018a) ENLIGHT: European network for light ion hadron therapy. Radiother Oncol 128, 76–82.
    1. Dosanjh M, Jones B, Pawelke J, Pruschy M and Sorensen BS (2018b) Overview of research and therapy facilities for radiobiological experimental work in particle therapy. Report from the European Particle Therapy Network radiobiology group. Radiother Oncol 128, 14–18.
    1. Durante M and Debus J (2018) Heavy charged particles: does improved precision and higher biological effectiveness translate to better outcome in patients? Semin Radiat Oncol 28, 160–167.
    1. Durante M and Flanz J (2019) Charged particle beams to cure cancer: strengths and challenges. Semin Oncol 46, 219–225.
    1. Durante M, Golubev A, Park W‐Y and Trautmann C (2019) Applied nuclear physics at the new high‐energy particle accelerator facilities. Phys Rep 800, 1–37.
    1. Durante M and Loeffler JS (2010) Charged particles in radiation oncology. Nat Rev Clin Oncol 7, 37–43.
    1. Durante M and Paganetti H (2016) Nuclear physics in particle therapy: a review. Rep Prog Phys 79, 096702.
    1. Eekers DBP, in't Ven L, Roelofs E, Postma A, Alapetite C, Burnet NG, Calugaru V, Compter I, Coremans IEM, Høyer M et al (2018) The EPTN consensus‐based atlas for CT‐ and MR‐based contouring in neuro‐oncology. Radiother Oncol 128, 37–43.
    1. Gietelink L, Wouters MW, Bemelman WA, Dekker JW, Tollenaar RA, Tanis PJ and Dutch Surgical Colorectal Cancer Audit Group (2016) Reduced 30‐day mortality after laparoscopic colorectal cancer surgery: a population based study from the Dutch Surgical Colorectal Audit (DSCA). Ann Surg 264, 135–140.
    1. Grau C, Baumann M and Weber DC (2018) Optimizing clinical research and generating prospective high‐quality data in particle therapy in Europe: introducing the European Particle Therapy Network (EPTN). Radiother Oncol 128, 1–3.
    1. Haas‐Kogan D, Indelicato D, Paganetti H, Esiashvili N, Mahajan A, Yock T, Flampouri S, MacDonald S, Fouladi M, Stephen K et al (2018) National Cancer Institute workshop on proton therapy for children: considerations regarding brainstem injury. Int J Radiat Oncol Biol Phys 101, 152–168.
    1. Knopf A, Bert C, Heath E, Nill S, Kraus K, Richter D, Hug E, Pedroni E, Safai S, Albertini F et al (2010) Special report: workshop on 4D‐treatment planning in actively scanned particle therapy–recommendations, technical challenges, and future research directions. Med Phys 37, 4608–4614.
    1. Lambin P, Zindler J, Vanneste B, van de Voorde L, Jacobs M, Eekers D, Peerlings J, Reymen B, Larue RT, Deist TM et al (2015) Modern clinical research: how rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta Oncol 54, 1289–1300.
    1. Lambrecht M, Eekers DBP, Alapetite C, Burnet NG, Calugaru V, Coremans IEM, Fossati P, Hoyer M, Langendijk JA, Mendez Romero A et al (2018) Radiation dose constraints for organs at risk in neuro‐oncology; the European Particle Therapy Network consensus. Radiother Oncol 128, 26–36.
    1. Langendijk JA, Boersma LJ, Rasch CRN, van Vulpen M, Reitsma JB, van der Schaaf A and Schuit E (2018a) Clinical trial strategies to compare protons with photons. Semin Radiat Oncol 28, 79–87.
    1. Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M and Verheij M (2013) Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model‐based approach. Radiother Oncol 107, 267–273.
    1. Langendijk JA, Orecchia R, Haustermans K, Zips D, Balosso J, Lacombe D, Lievens Y, Weber DC, Grau C and Troost EGC (2018b) Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol 128, 9–13.
    1. Odei B, Frandsen JE, Boothe D, Ermoian RP and Poppe MM (2017) Patterns of care in proton radiation therapy for pediatric central nervous system malignancies. Int J Radiat Oncol Biol Phys 97, 60–63.
    1. Oelfke U and Bortfeld T (2003) Optimization of physical dose distributions with hadron beams: comparing photon IMRT with IMPT. Technol Cancer Res Treat 2, 401–412.
    1. Potter R, Balosso J, Baumann M, Bert C, Davies J, Enghardt W, Fossati P, Harris S, Jones B, Kramer M et al (2018) Union of light ion therapy centers in Europe (ULICE EC FP7) – objectives and achievements of joint research activities. Radiother Oncol 128, 83–100.
    1. Price J, Hall E, West C and Thomson D (2020) TORPEdO – a phase III trial of intensity‐modulated proton beam therapy versus intensity‐modulated radiotherapy for multi‐toxicity reduction in oropharyngeal cancer. Clin Oncol (R Coll Radiol) 32, 84–88.
    1. Relton C, Torgerson D, O'Cathain A and Nicholl J (2010) Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ 340, c1066.
    1. Romero J, Cardenes H, la Torre A, Valcarcel F, Magallon R, Regueiro C and Aragon G (1993) Chordoma: results of radiation therapy in eighteen patients. Radiother Oncol 29, 27–32.
    1. Rwigema JM, Langendijk JA, Paul van der Laan H, Lukens JN, Swisher‐McClure SD and Lin A (2019) A model‐based approach to predict short‐term toxicity benefits with proton therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys 104, 553–562.
    1. Sakthivel V, Ganesh KM, McKenzie C, Boopathy R and Selvaraj J (2019) Second malignant neoplasm risk after craniospinal irradiation in X‐ray‐based techniques compared to proton therapy. Australas Phys Eng Sci Med 42, 201–209.
    1. Schneider U, Halg RA, Baiocco G and Lomax T (2016) Neutrons in proton pencil beam scanning: parameterization of energy, quality factors and RBE. Phys Med Biol 61, 6231–6242.
    1. Shen CJ, Hu C, Ladra MM, Narang AK, Pollack CE and Terezakis SA (2017) Socioeconomic factors affect the selection of proton radiation therapy for children. Cancer 123, 4048–4056.
    1. Specht HM, Neff T, Reuschel W, Wagner FM, Kampfer S, Wilkens JJ, Petry W and Combs SE (2015) Paving the road for modern particle therapy – what can we learn from the experience gained with fast neutron therapy in Munich? Front Oncol 5, 262.
    1. Stock M, Georg D, Ableitinger A, Zechner A, Utz A, Mumot M, Kragl G, Hopfgartner J, Gora J, Bohlen T et al (2018) The technological basis for adaptive ion beam therapy at MedAustron: status and outlook. Z Med Phys 28, 196–210.
    1. van de Water S, Albertini F, Weber DC, Heijmen BJM, Hoogeman MS and Lomax AJ (2018) Anatomical robust optimization to account for nasal cavity filling variation during intensity‐modulated proton therapy: a comparison with conventional and adaptive planning strategies. Phys Med Biol 63, 025020.
    1. Weber DC, Abrunhosa‐Branquinho A, Bolsi A, Kacperek A, Dendale R, Geismar D, Bachtiary B, Hall A, Heufelder J, Herfarth K et al (2017) Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiother Oncol 124, 185–189.
    1. Weber DC, Grau C, Lim PS, Georg D and Lievens Y (2019) Bringing Europe together in building clinical evidence for proton therapy – the EPTN‐ESTRO‐EORTC endeavor. Acta Oncol 58, 1340–1342.
    1. Weber DC, Habrand JL, Hoppe BS, Hill Kayser C, Laack NN, Langendijk JA, MacDonald SM, McGovern SL, Pater L, Perentesis JP et al (2018) Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiother Oncol 128, 44–55.
    1. Weber DC, Lim PS, Tran S, Walser M, Bolsi A, Kliebsch U, Beer J, Bachtiary B, Lomax T and Pica A (2020) Proton therapy for brain tumours in the area of evidence‐based medicine. Br J Radiol 93, 20190237.
    1. Weber DC, Malyapa R, Albertini F, Bolsi A, Kliebsch U, Walser M, Pica A, Combescure C, Lomax AJ and Schneider R (2016) Long term outcomes of patients with skull‐base low‐grade chondrosarcoma and chordoma patients treated with pencil beam scanning proton therapy. Radiother Oncol 120, 169–174.
    1. Widder J, van der Schaaf A, Lambin P, Marijnen CA, Pignol JP, Rasch CR, Slotman BJ, Verheij M and Langendijk JA (2016) The quest for evidence for proton therapy: model‐based approach and precision medicine. Int J Radiat Oncol Biol Phys 95, 30–36.
    1. Wilson RR (1946) Radiological use of fast protons. Radiology 47, 487–491.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir